Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients

Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Kameda, Hideto [verfasserIn] Amano, Koichi [verfasserIn] Sekiguchi, Naoya [verfasserIn] Takei, Hirofumi [verfasserIn] Ogawa, Hiroe [verfasserIn] Nagasawa, Hayato [verfasserIn] Takeuchi, Tsutomu [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2004

Übergeordnetes Werk:	Enthalten in: Modern rheumatology - Oxford : Oxford University Press, 2000, 14(2004), 6 vom: Dez., Seite 442-446
Übergeordnetes Werk:	volume:14 ; year:2004 ; number:6 ; month:12 ; pages:442-446

Links:	Volltext

DOI / URN:	10.1007/s10165-004-0340-3

Katalog-ID:	SPR00901831X

Internformat


LEADER	01000caa a22002652 4500
001	SPR00901831X
003	DE-627
005	20230519075557.0
007	cr uuu---uuuuu
008	201005s2004 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10165-004-0340-3 \|2 doi
035			\|a (DE-627)SPR00901831X
035			\|a (SPR)s10165-004-0340-3-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
082	0	4	\|a 610 \|q ASE
084			\|a 44.83 \|2 bkl
100	1		\|a Kameda, Hideto \|e verfasserin \|4 aut
245	1	0	\|a Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
264		1	\|c 2004
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.
700	1		\|a Amano, Koichi \|e verfasserin \|4 aut
700	1		\|a Sekiguchi, Naoya \|e verfasserin \|4 aut
700	1		\|a Takei, Hirofumi \|e verfasserin \|4 aut
700	1		\|a Ogawa, Hiroe \|e verfasserin \|4 aut
700	1		\|a Nagasawa, Hayato \|e verfasserin \|4 aut
700	1		\|a Takeuchi, Tsutomu \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Modern rheumatology \|d Oxford : Oxford University Press, 2000 \|g 14(2004), 6 vom: Dez., Seite 442-446 \|w (DE-627)320627497 \|w (DE-600)2023498-3 \|x 1439-7609 \|7 nnns
773	1	8	\|g volume:14 \|g year:2004 \|g number:6 \|g month:12 \|g pages:442-446
856	4	0	\|u https://dx.doi.org/10.1007/s10165-004-0340-3 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_40
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_151
912			\|a GBV_ILN_170
912			\|a GBV_ILN_224
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
936	b	k	\|a 44.83 \|q ASE
951			\|a AR
952			\|d 14 \|j 2004 \|e 6 \|c 12 \|h 442-446

Indexfelder

author_variant	h k hk k a ka n s ns h t ht h o ho h n hn t t tt
matchkey_str	article:14397609:2004----::atrpeitnteepneoodsmtorxtteaynainsihhuaodrhi
hierarchy_sort_str	2004
bklnumber	44.83
publishDate	2004
allfields	10.1007/s10165-004-0340-3 doi (DE-627)SPR00901831X (SPR)s10165-004-0340-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Kameda, Hideto verfasserin aut Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required. Amano, Koichi verfasserin aut Sekiguchi, Naoya verfasserin aut Takei, Hirofumi verfasserin aut Ogawa, Hiroe verfasserin aut Nagasawa, Hayato verfasserin aut Takeuchi, Tsutomu verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 14(2004), 6 vom: Dez., Seite 442-446 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:14 year:2004 number:6 month:12 pages:442-446 https://dx.doi.org/10.1007/s10165-004-0340-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 14 2004 6 12 442-446
spelling	10.1007/s10165-004-0340-3 doi (DE-627)SPR00901831X (SPR)s10165-004-0340-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Kameda, Hideto verfasserin aut Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required. Amano, Koichi verfasserin aut Sekiguchi, Naoya verfasserin aut Takei, Hirofumi verfasserin aut Ogawa, Hiroe verfasserin aut Nagasawa, Hayato verfasserin aut Takeuchi, Tsutomu verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 14(2004), 6 vom: Dez., Seite 442-446 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:14 year:2004 number:6 month:12 pages:442-446 https://dx.doi.org/10.1007/s10165-004-0340-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 14 2004 6 12 442-446
allfields_unstemmed	10.1007/s10165-004-0340-3 doi (DE-627)SPR00901831X (SPR)s10165-004-0340-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Kameda, Hideto verfasserin aut Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required. Amano, Koichi verfasserin aut Sekiguchi, Naoya verfasserin aut Takei, Hirofumi verfasserin aut Ogawa, Hiroe verfasserin aut Nagasawa, Hayato verfasserin aut Takeuchi, Tsutomu verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 14(2004), 6 vom: Dez., Seite 442-446 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:14 year:2004 number:6 month:12 pages:442-446 https://dx.doi.org/10.1007/s10165-004-0340-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 14 2004 6 12 442-446
allfieldsGer	10.1007/s10165-004-0340-3 doi (DE-627)SPR00901831X (SPR)s10165-004-0340-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Kameda, Hideto verfasserin aut Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required. Amano, Koichi verfasserin aut Sekiguchi, Naoya verfasserin aut Takei, Hirofumi verfasserin aut Ogawa, Hiroe verfasserin aut Nagasawa, Hayato verfasserin aut Takeuchi, Tsutomu verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 14(2004), 6 vom: Dez., Seite 442-446 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:14 year:2004 number:6 month:12 pages:442-446 https://dx.doi.org/10.1007/s10165-004-0340-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 14 2004 6 12 442-446
allfieldsSound	10.1007/s10165-004-0340-3 doi (DE-627)SPR00901831X (SPR)s10165-004-0340-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Kameda, Hideto verfasserin aut Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required. Amano, Koichi verfasserin aut Sekiguchi, Naoya verfasserin aut Takei, Hirofumi verfasserin aut Ogawa, Hiroe verfasserin aut Nagasawa, Hayato verfasserin aut Takeuchi, Tsutomu verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 14(2004), 6 vom: Dez., Seite 442-446 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:14 year:2004 number:6 month:12 pages:442-446 https://dx.doi.org/10.1007/s10165-004-0340-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 14 2004 6 12 442-446
language	English
source	Enthalten in Modern rheumatology 14(2004), 6 vom: Dez., Seite 442-446 volume:14 year:2004 number:6 month:12 pages:442-446
sourceStr	Enthalten in Modern rheumatology 14(2004), 6 vom: Dez., Seite 442-446 volume:14 year:2004 number:6 month:12 pages:442-446
format_phy_str_mv	Article
institution	findex.gbv.de
dewey-raw	610
isfreeaccess_bool	false
container_title	Modern rheumatology
authorswithroles_txt_mv	Kameda, Hideto @@aut@@ Amano, Koichi @@aut@@ Sekiguchi, Naoya @@aut@@ Takei, Hirofumi @@aut@@ Ogawa, Hiroe @@aut@@ Nagasawa, Hayato @@aut@@ Takeuchi, Tsutomu @@aut@@
publishDateDaySort_date	2004-12-01T00:00:00Z
hierarchy_top_id	320627497
dewey-sort	3610
id	SPR00901831X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR00901831X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519075557.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2004 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-004-0340-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR00901831X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-004-0340-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kameda, Hideto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Amano, Koichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sekiguchi, Naoya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takei, Hirofumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ogawa, Hiroe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagasawa, Hayato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takeuchi, Tsutomu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">14(2004), 6 vom: Dez., Seite 442-446</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:6</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:442-446</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-004-0340-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2004</subfield><subfield code="e">6</subfield><subfield code="c">12</subfield><subfield code="h">442-446</subfield></datafield></record></collection>
author	Kameda, Hideto
spellingShingle	Kameda, Hideto ddc 610 bkl 44.83 Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
authorStr	Kameda, Hideto
ppnlink_with_tag_str_mv	@@773@@(DE-627)320627497
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1439-7609
topic_title	610 ASE 44.83 bkl Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
topic	ddc 610 bkl 44.83
topic_unstemmed	ddc 610 bkl 44.83
topic_browse	ddc 610 bkl 44.83
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Modern rheumatology
hierarchy_parent_id	320627497
dewey-tens	610 - Medicine & health
hierarchy_top_title	Modern rheumatology
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)320627497 (DE-600)2023498-3
title	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
ctrlnum	(DE-627)SPR00901831X (SPR)s10165-004-0340-3-e
title_full	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
author_sort	Kameda, Hideto
journal	Modern rheumatology
journalStr	Modern rheumatology
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2004
contenttype_str_mv	txt
container_start_page	442
author_browse	Kameda, Hideto Amano, Koichi Sekiguchi, Naoya Takei, Hirofumi Ogawa, Hiroe Nagasawa, Hayato Takeuchi, Tsutomu
container_volume	14
class	610 ASE 44.83 bkl
format_se	Elektronische Aufsätze
author-letter	Kameda, Hideto
doi_str_mv	10.1007/s10165-004-0340-3
dewey-full	610
author2-role	verfasserin
title_sort	factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
title_auth	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
abstract	Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.
abstractGer	Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.
abstract_unstemmed	Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333
container_issue	6
title_short	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
url	https://dx.doi.org/10.1007/s10165-004-0340-3
remote_bool	true
author2	Amano, Koichi Sekiguchi, Naoya Takei, Hirofumi Ogawa, Hiroe Nagasawa, Hayato Takeuchi, Tsutomu
author2Str	Amano, Koichi Sekiguchi, Naoya Takei, Hirofumi Ogawa, Hiroe Nagasawa, Hayato Takeuchi, Tsutomu
ppnlink	320627497
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s10165-004-0340-3
up_date	2024-07-04T00:20:30.419Z
_version_	1803605697280081920
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR00901831X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519075557.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2004 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-004-0340-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR00901831X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-004-0340-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kameda, Hideto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Amano, Koichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sekiguchi, Naoya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takei, Hirofumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ogawa, Hiroe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagasawa, Hayato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takeuchi, Tsutomu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">14(2004), 6 vom: Dez., Seite 442-446</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:6</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:442-446</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-004-0340-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2004</subfield><subfield code="e">6</subfield><subfield code="c">12</subfield><subfield code="h">442-446</subfield></datafield></record></collection>
score	7.398796

Nicht das Richtige dabei?

Schreiben Sie uns!

Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?